01—Abstract
Summary
Summary of the 10-K filed March 14, 2003. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. reported robust revenue growth in 2002, driven primarily by strong sales of Viread, its HIV treatment, which nearly doubled its revenue contribution compared to 2001.
AmBisome, an antifungal, also showed solid growth, contributing significantly to the company's overall performance. The company's acquisition of Triangle Pharmaceuticals in January 2003 marked a strategic move to bolster its antiviral pipeline, particularly for HIV and Hepatitis B, with the inclusion of emtricitabine and other promising drug candidates. Financially, Gilead achieved operating profitability in 2002 after years of losses, indicating a positive trajectory.
However, the company faces ongoing challenges, including increasing competition in key therapeutic areas and the complexities of integrating new acquisitions. Gilead also highlighted its commitment to global health initiatives, announcing plans to supply Viread at cost to developing countries, demonstrating a balance between commercial objectives and social responsibility.
02—Key points
Key Highlights
- Total revenues increased significantly to $466.8 million in 2002, up from $233.8 million in 2001, largely driven by Viread sales.
- Viread product sales reached $225.8 million in 2002, accounting for 48% of total revenues, a substantial increase from $15.6 million in 2001.
- AmBisome sales grew 13% to $185.7 million in 2002, representing 40% of total product sales.
- Gilead achieved operating income of $81.0 million in 2002, marking a shift to profitability from an operating loss in 2001.
- The acquisition of Triangle Pharmaceuticals for $525.0 million was completed in January 2003, strengthening Gilead's antiviral portfolio, particularly for HIV and Hepatitis B.
- Research and Development expenses decreased to $134.8 million in 2002 from $185.6 million in 2001, partly due to the divestiture of the oncology assets.
- Gilead's common stock is traded on The Nasdaq Stock Market under the symbol 'GILD'.
03—Questions
Frequently Asked Questions
What are Gilead's main revenue drivers as of the 2002 fiscal year?
Gilead's primary revenue drivers are Viread, an HIV treatment, and AmBisome, an antifungal medication. In 2002, Viread generated $225.8 million in sales, representing 48% of total revenues, while AmBisome generated $185.7 million, accounting for 40% of total product sales.
What was Gilead's financial performance in 2002 compared to 2001?
Gilead saw significant improvement in 2002. Total revenues more than doubled to $466.8 million, up from $233.8 million in 2001. Critically, the company achieved operating profitability in 2002 with $81.0 million in operating income, a reversal from an operating loss of $120.7 million in 2001.
What is the significance of the Triangle Pharmaceuticals acquisition?
Gilead acquired Triangle Pharmaceuticals in January 2003 for $525.0 million. This acquisition was strategic, aimed at strengthening Gilead's antiviral pipeline by adding Triangle's drug candidates, such as emtricitabine for HIV and Hepatitis B, to its portfolio.
04—Continue